Protective effect of antimalarials on the most frequently affected damage domains in SLE: Data from a multiethnic Latin American cohort.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Quintana Rosana, Pons-Estel Guillermo J, Wojdyla Daniel, Alarcón Graciela S, Serrano Rosa María, Ugarte-Gil Manuel, Pimentel-Quiroz Víctor, Catoggio Luis J, Scolnik Marina, Sacnun Mónica, Saurit Verónica, Caeiro Francisco, Alvarellos Alejandro, Sarano Judith, García Mercedes, Drenkard Cristina, Berbotto Guillermo, Sato Emilia, Bonfa Eloisa, Borba Eduardo Ferreira, Costallat Lilian, Xavier Ricardo, Tavares Brenol Joao C, Da Silva Nilzio A, Massardo Loreto, Neira Oscar, Vásquez Gloria, Gonzalez Luis Alonso, Guibert-Toledano Marlene, Cardiel Mario H, Pascual-Ramos Virginia, García de la Torre Ignacio, Barile Leonor, Silveira Luis H, Amigo Mary-Carmen, Sauza Del Pozo María Josefina, Acevedo-Vásquez Eduardo M, Segami María Inés, Chacón-Díaz Rosa, Zavala-Flores Ernesto, Pons-Estel Bernardo A
Аннотация
ObjectiveTo assess the effect of antimalarials (AMs) on overall damage and on its most frequently affected domains, as measured by the Systemic Lupus International Collaborating Clinics Damage Index (SDI) in patients from the GLADEL cohort.MethodsNew damage was defined as a ≥1 point increase in SDI since cohort entry. AMs users were those who received AMs for at least 6 months after entering the cohort. AMs users and non-users were matched for age, sex, ethnicity, and baseline SDI using stratified random sampling. Two comparisons were carried out: patients with and without new damage, and AM users versus non-users. Propensity score matching was used to determine the effect of AM use on the most frequently affected damage domains.ResultsA total of 850 patients were included; 419 (49.3%) were AM users and 431 (50.7%) non-users. During a median follow-up of 48.5 (IQR 19.3, 69.0) months, 472 (55.5%) developed damage. The most affected domains were skin (18.4%), renal (14.6%), neuropsychiatric (10.8%), musculoskeletal (6.9%), and cardiovascular (4.5%). AMs use was associated with a lower proportion of patients accruing damage at follow-up (170 [40.6%] vs 208 [48.3%]; p = .028). AMs were protective against overall damage (HR 0.7, 95% CI [0.5-0.9]; p = .002), renal (HR 0.4, 95% CI [0.3-0.6]; p < .001), and neuropsychiatric damage (HR 0.5, 95% CI [0.3-0.9]; p = .022).ConclusionAM use is independently associated with a lower probability of overall, renal, and neuropsychiatric damage accrual. These findings support early and sustained AM treatment in lupus patients, unless contraindicated.